NCT00003017View on ClinicalTrials.gov

Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 1997

Study Completion Date

August 31, 2005

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

recombinant interleukin-12

Trial Locations (9)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

10461

Albert Einstein Comprehensive Cancer Center, The Bronx

14642

University of Rochester Cancer Center, Rochester

15213

University of Pittsburgh Cancer Institute, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

02215

Beth Israel Deaconess Medical Center, Boston

08822

Hunterdon Regional Cancer Center, Flemington

07601

CCOP - Northern New Jersey, Hackensack

37232-6838

Vanderbilt Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT00003017 - Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix | Biotech Hunter | Biotech Hunter